“Soothing the Debate: Bonjela to Vanish from Supermarket Shelves Amidst Controversy”

Bonjela Teething Gel and Bonjela Mouth Ulcer Gel to be Removed from Supermarket Shelves

Concerns Over Toxicity Levels Lead to Reclassification

Bonjela Teething Gel and Bonjela Mouth Ulcer Gel, popular products used to alleviate the pain and discomfort associated with teething and mouth ulcers, will no longer be available on supermarket shelves in Australia starting October 1. The Therapeutic Goods Administration (TGA) has reclassified these products from Schedule 1 medicines to Schedule 2 medicines. This change is due to concerns over toxicity levels resulting from misuse.

The reclassification of these infant and toddler products means that they will only be available for purchase at pharmacies. Woolworths has already ceased orders for Bonjela products, and any remaining stock is expected to be sold out by the end of September. Coles is also in the process of discontinuing sales of Bonjela and is currently running down its stock.

Risks of Misuse and Overdose

The active ingredient in Bonjela products, choline salicylate, is a non-steroidal anti-inflammatory (NSAID) that can lead to toxicity when overdosed. Misuse of these products can occur when they are not used as directed, such as using too much of the product, using it too frequently, or using it over an extended period of time.

Choline salicylate is also found in other teething products, as well as products used to relieve pain, inflammation, and discomfort associated with mouth ulcers, new dentures, or braces. The risk of overdose toxicity is particularly high in children.

Professional Advice and Schedule 2 Classification

Pharmacist Alyssa Fusillo emphasizes the importance of using these medications at the recommended dose, frequency, and duration. She advises that Choline Salicylate should not be used for more than three days, no more than six times in three hours, and not exceeding three hours between doses.

The reclassification of Bonjela products to Schedule 2 means that parents will now have access to professional advice each time they purchase these items from a pharmacy. This move aims to ensure that consumers are properly informed about the safe and appropriate use of these products.

Alternatives and Lack of Evidence

For parents who may need relief beyond the three-day timeframe, Fusillo suggests exploring other options such as chilled teething rusks, oral analgesics like paracetamol and ibuprofen, and distractions like offering cool foods such as yoghurt to soothe teething discomfort. However, she also notes that the therapeutic guidelines in Australia do not recommend teething gels, including those containing choline salicylate, due to a lack of evidence regarding their effectiveness and potential harm.

Conclusion

The reclassification of Bonjela Teething Gel and Bonjela Mouth Ulcer Gel from Schedule 1 to Schedule 2 medicines reflects concerns over potential toxicity levels resulting from misuse. While these products will no longer be readily available on supermarket shelves, their reclassification will ensure that parents have access to professional advice at pharmacies when purchasing them. It is crucial for parents to follow the recommended dosage, frequency, and duration of use to prevent any potential harm. Exploring alternative methods, with advice from healthcare professionals, can also provide relief for teething pains beyond the recommended three-day period.